Why Investors Should Watch Teva Despite Regional Risks

2025-05-23 12:52:03 ET

Summary

• Despite the lack of cautious enthusiasm from retail investors in Teva, it continues to beat consensus estimates by wide margins and has once again raised its 2025 financial guidance.
• I highlight Austedo, Uzedy, the launch of biosimilars, and the more than successful development of duvakitug for the treatment of IBD in collaboration with Sanofi as key growth drivers.
• Moody's and Fitch also recently raised the Israeli pharmaceutical giant's credit ratings thanks to the continued strengthening of its balance sheet.
• The corresponding growth of Wall Street interest in Teva Pharmaceuticals, on May 20, announced an increase in its bond offering from $2 billion to $2.3 billion.
• In this article, I will reveal additional factors that, in my opinion, make Teva a stock with an outstanding risk/reward ratio despite the growing instability in the Middle xEast.

Since the first days of 2025, it has been an eventful year for Teva Pharmaceuticals (NYSE: TEVA ). Some of them were the first significant steps that contributed to the return of the Israeli giant to the forefront of the immunology and neuroscience markets, while others have left me worried....

Read the full article on Seeking Alpha

For further details see: